SFSIG
ALXN

San Francisco Sentry Investment Group’s Alexion Pharmaceuticals ALXN Stock Holding History

San Francisco Sentry Investment Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$5K Hold
26
– – ﹤0.01% 576
2021
Q1 		$4K Hold
26
– – ﹤0.01% 625
2020
Q4 		$4K Hold
26
– – ﹤0.01% 591
2020
Q3 		$3K Hold
26
– – ﹤0.01% 593
2020
Q2 		$3K Sell
26
-167
-87% -$17.7K ﹤0.01% 581
2020
Q1 		$17K Buy
193
+24
+14% +$2.35K 0.01% 406
2019
Q4 		$18K Sell
169
-22
-12% -$2.35K 0.01% 501
2019
Q3 		$19K Buy
191
+176
+1,173% +$19.8K 0.01% 494
2019
Q2 		$2K Sell
15
-207
-93% -$26.7K ﹤0.01% 791
2019
Q1 		$30K Sell
222
-1
-0.4% -$124 0.01% 452
2018
Q4 		$22K Sell
223
-13
-6% -$1.54K 0.01% 468
2018
Q3 		$33K Sell
236
-427
-64% -$53.6K 0.01% 445
2018
Q2 		$83K Buy
663
+618
+1,373% +$72.2K 0.03% 334
2018
Q1 		$5K Hold
45
– – ﹤0.01% 771
2017
Q4 		$6K Hold
45
– – ﹤0.01% 743
2017
Q3 		$6K Buy
45
+30
+200% +$4.08K ﹤0.01% 735
2017
Q2 		$2K Buy
+15
New +$1.75K ﹤0.01% 708
2014
Q4 		– Sell
-500
Closed -$83K – 494
2014
Q3 		$83K Hold
500
– – 0.04% 242
2014
Q2 		$78K Hold
500
– – 0.04% 262
2014
Q1 		$76K Buy
+500
New +$79.5K 0.02% 302

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

San Francisco Sentry Investment Group's ALXN Position: Q2 2021 in Review

San Francisco Sentry Investment Group held its Alexion Pharmaceuticals (ALXN) position steady in Q2 2021 at 26 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #576.

San Francisco Sentry Investment Group first reported a position in ALXN in Q1 2014 and has held it in 20 quarters since. The position peaked at $83K in Q2 2018. 708 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • San Francisco Sentry Investment Group held 26 shares of Alexion Pharmaceuticals worth $5K as of Q2 2021.
  • San Francisco Sentry Investment Group left its Alexion Pharmaceuticals share count unchanged in Q2 2021.
  • Alexion Pharmaceuticals made up ﹤0.01% of San Francisco Sentry Investment Group's portfolio in Q2 2021, its #576 holding.
  • San Francisco Sentry Investment Group first reported a position in Alexion Pharmaceuticals in Q1 2014 and has held it in 20 quarters since.
  • San Francisco Sentry Investment Group's Alexion Pharmaceuticals position peaked at $83K in Q2 2018.
  • 708 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on San Francisco Sentry Investment Group's 13F filing for Q2 2021, filed 2 Aug 2021.